^
Association details:
Biomarker:MTOR E2419K
Cancer:Urothelial Cancer
Drug:everolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

Excerpt:
Examination of the sequencing data for biologically plausible mechanisms of sensitivity to everolimus or pazopanib revealed two mutations in mTOR, the target of everolimus.
DOI:
10.1158/2159-8290.CD-13-0353
Trial ID: